Fumie Abe
Impact in
- Pharmacology top 5%
- Microbial Natural Products and Biosynthesis
- Fungal Biology and Applications
- Biotechnology top 10%
- Marine Sponges and Natural Products
Papers in
-
- Histone Deacetylase Inhibitors Research 4
- Signaling Pathways in Disease 2
- Oncology 14
- Drug Transport and Resistance Mechanisms 9
- Co-authors
- Motohiro Hino (9 shared papers)Kazutoshi Sakamoto (3 shared papers)Takashi Fujii (4 shared papers)Shigetada Furukawa (5 shared papers)Hiroaki Mori (4 shared papers)Michizane Hashimoto (4 shared papers)YASUHISA TSURUMI (2 shared papers)Shigehiro Takase (2 shared papers)
In The Last Decade
Fumie Abe
26 papers receiving 565 citations
Peers
Comparison fields: 5 of 84
- Pharmacology 191
- Biotechnology 74
- Toxicology 23
- Organic Chemistry 181
- Pharmacology 38
Countries citing papers authored by Fumie Abe
This map shows the geographic impact of Fumie Abe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fumie Abe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fumie Abe more than expected).
Fields of papers citing papers by Fumie Abe
This network shows the impact of papers produced by Fumie Abe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fumie Abe. The network helps show where Fumie Abe may publish in the future.
Co-authors
The 25 scholars most cited alongside Fumie Abe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 27 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2003 | 193 | |
| 2 | 1996 | 114 | |
| 3 | 2003 | 41 | |
| 4 | FR235222, a fungal metabolite, is a novel immunosuppressant that inhibits mammalian histone deacetylase (HDAC) II. Biological activities in animal models. | 2003 | 38 |
| 5 | 2009 | 35 | |
| 6 | 2004 | 27 | |
| 7 | 2005 | 22 | |
| 8 | 2006 | 17 | |
| 9 | 2008 | 14 | |
| 10 | 2003 | 12 | |
| 11 | 2005 | 10 | |
| 12 | 2008 | 10 | |
| 13 | 2006 | 8 | |
| 14 | 2009 | 8 | |
| 15 | 2004 | 7 | |
| 16 | 2010 | 5 | |
| 17 | 2007 | 3 | |
| 18 | Panipenem does not alter the pharmacokinetics of the active metabolite of irinotecan SN-38 and inactive metabolite SN-38 glucuronide (SN-38G) in rats. | 2011 | 3 |
| 19 | 2003 | 3 | |
| 20 | 2010 | 2 |
About Fumie Abe
Fumie Abe is a scholar working on Molecular Biology, Oncology, Pharmacology, Pediatrics, Perinatology and Child Health and Infectious Diseases, having authored 27 papers that have together received 581 indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (9 papers), Pharmacological Effects and Toxicity Studies (4 papers), Histone Deacetylase Inhibitors Research (4 papers), Pharmacogenetics and Drug Metabolism (3 papers), Antibiotics Pharmacokinetics and Efficacy (3 papers), Bioactive Compounds and Antitumor Agents (3 papers), Fungal Biology and Applications (3 papers) and Signaling Pathways in Disease (2 papers). The work is most often cited by research in Pharmacology (191 citations), Biotechnology (74 citations), Toxicology (23 citations), Organic Chemistry (181 citations) and Pharmacology (38 citations). Fumie Abe has collaborated with scholars based in Japan, Norway and Croatia. Frequent co-authors include Motohiro Hino, Kazutoshi Sakamoto, Takashi Fujii, Shigetada Furukawa, Hiroaki Mori, Michizane Hashimoto, YASUHISA TSURUMI, Shigehiro Takase, Yasuharu Urano and Michio Yamashita. Their work appears in journals such as The Journal of Antibiotics, Life Sciences, Biological and Pharmaceutical Bulletin, Inflammation Research and Bioscience Biotechnology and Biochemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.